Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday

Key Points

• Milestone Pharmaceuticals is projected to issue its Q4 2025 results before the market opens on March 31, with analysts forecasting EPS of ($0.1602); the company previously reported ($0.16) EPS that beat estimates but posted a large revenue shortfall of $1.44M versus $37.52M expected.
• Shares opened at $1.26 with a market cap of about $107.3M and a one‑year range of $0.63–$3.06, while analysts show mixed views—3 Buys, 2 Holds and 1 Sell—giving an average target price of $8.00 and an overall "Hold" rating.
• Insiders have been selling recently (CEO Joseph Oliveto sold 34,523 shares on Jan 26 and insiders sold 113,693 shares in the last three months), leaving insiders with 19.5% ownership, while institutional investors hold 86.18% of the stock.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.1602) per share for the quarter. Parties may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 20, 2026 at 8:30 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its earnings results on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to analysts' expectations of $37.52 million. On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $1.26 on Tuesday. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $3.06. The stock has a market capitalization of $107.31 million, a price-to-earnings ratio of -1.59 and a beta of 0.48. The company has a 50-day simple moving average of $1.79 and a 200-day simple moving average of $1.99. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Analyst Upgrades and Downgrades

MIST has been the topic of several recent research reports. Zacks Research cut Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company boosted their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an "overweight" rating in a report on Tuesday, December 16th. TD Cowen upgraded Milestone Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Monday, December 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $8.00.

Insider Buying and Selling

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 34,523 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the sale, the chief executive officer directly owned 482,744 shares in the company, valued at approximately $931,695.92. The trade was a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 113,693 shares of company stock valued at $233,347 over the last three months. 19.50% of the stock is currently owned by company insiders.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in MIST. Two Sigma Investments LP purchased a new stake in Milestone Pharmaceuticals during the third quarter worth about $1,333,000. Millennium Management LLC purchased a new position in Milestone Pharmaceuticals in the third quarter valued at about $803,000. UBS Group AG increased its holdings in Milestone Pharmaceuticals by 23.2% in the third quarter. UBS Group AG now owns 397,534 shares of the company's stock valued at $795,000 after buying an additional 74,886 shares in the last quarter. Guardian Wealth Advisors LLC NC lifted its position in shares of Milestone Pharmaceuticals by 25.2% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 263,200 shares of the company's stock valued at $532,000 after acquiring an additional 53,000 shares during the period. Finally, Aptus Capital Advisors LLC lifted its position in shares of Milestone Pharmaceuticals by 25.2% during the 4th quarter. Aptus Capital Advisors LLC now owns 263,200 shares of the company's stock valued at $532,000 after acquiring an additional 53,000 shares during the period. Institutional investors and hedge funds own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.